Home > Healthcare > Pharmaceuticals > Active Pharmaceutical Ingredients > Nuclear Medicine Market

Nuclear Medicine Market Share

Report ID: GMI12229
Published Date: Nov 2024
Report Format: PDF

Download Free Sample

Nuclear Medicine Market Share

The market is dominated by some of the major market players operating worldwide. The market is competitive in nature, with major organizations, local small players, and start-ups joining the industry competition. Key players are entering partnerships with hospitals, academic institutions, and smaller biotech firms to develop innovative radiopharmaceuticals and expand treatment capabilities. Leading companies, such as Jubilant Pharma, Cardinal Health, Inc., Novartis AG, Lantheus, GE Healthcare, and Boston Scientific Corporation among others are increasing their portfolios in therapeutic radiopharmaceuticals, especially for targeted cancer treatment.

Nuclear Medicine Market Companies

Some of the eminent market participants operating in the nuclear medicine industry include:

Actinium Pharmaceuticals
Boston Scientific
Bracco
Cardinal Health
Curium Pharma
GE Healthcare
Jubilant Pharma
Lantheus
Novartis
RadioMedix
RLS Radiopharmacies
Siemens Healthineers
Sirtex
Sun Pharma
Theragenics

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global nuclear medicine industry was valued at around USD 13.6 billion in 2023 and is expected to exhibit growth at a CAGR of 16.3% from 2024 to 2032, driven by the increasing prevalence of cancer and cardiovascular diseases.

The diagnostics segment dominated the market with a revenue of around USD 9.4 billion in 2023, fueled by rising healthcare expenditures and infrastructure improvements in emerging markets.

The North America nuclear medicine market accounted for USD 7 billion in revenue in 2023 and is anticipated to grow at a CAGR of 15.6% between 2024 and 2032, supported by the region

Key players in the industry include Actinium Pharmaceuticals, Boston Scientific, Bracco, Cardinal Health, Curium Pharma, GE Healthcare, Jubilant Pharma, Lantheus, Novartis, RadioMedix, RLS Radiopharmacies, Siemens Healthineers, and Sirtex.